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Case summary:
Demographic details:
Mr. JS, male, Gudja
Referred from: GP
A 57-year-old Caucasian gentleman presented with bilateral progressive distal upper limb paraesthesiae, 
which he described as a feeling of  “heaviness” followed by distal lower limb and mild tongue parasthaesia. 
He complained of dysaesthetic symptoms in his upper limbs with intermittent burning and tingling and 
autonomic disturbances such as excessive sweating of the face, hands and legs. He later developed 
epigastric pain that radiated to the chest, which was not related to exercise. According to the patient, 
symptoms got worse after taking the influenza vaccine. On examination, he had gait disturbance with 
weaker left lower limb muscles. During his stay in hospital, he also developed slight dysarthria and 
diplopia, together with urinary retention and constipation. He had had a similar, though much less severe, 
episode six years previously where he was diagnosed with Guillain-Barré Syndrome based on his clinical 
features, EMG result and his high protein levels in the CSF (more than 8g/L). He was treated with IVIG 
and recovered completely. This was his second presentation of neuromuscular weakness and he was 
referred for immunoglobulin treatment and intensive physiotherapy.
Presenting complaint:
JS presented with progressive bilateral parasthaesia of the upper extremities. It was followed by bilateral 
lower limb and later, tongue parasthaesia. He had been referred to hospital due to epigastric pain that 
progressed to chest pain. His chest pain was associated with slight sweating and it did not radiate 
anywhere. It was exacerbated by inspiration. 
History of presenting complaint:
He suffered from a similar episode six years previously where he was diagnosed with GBS. He recovered 
completely after being treated with intravenous immunoglobulins (IVIG) and had no symptoms until this 
second presentation.
Past medical and surgical history:
Past medical history:
• Hypertension
• Diabetes
• Hypercholesterolemia 
• Gastro-oesophageal reflux disease
2Drug history:
Drug Dosage Frequency Type Reason
Metformin 500mg TDS Anti-diabetic Treatment for Diabetes Mellitus type 2
Perindopril 4mg Nocte ACE Inhibitor Treatment of hypertension
Simvastatin 20mg Nocte Lipid lowering agent Treatment of hypercholesterolaemia
Aspirin 75mg Once Daily Analgesic Ischaemic Heart Disease
Family history:
Father died of a myocardial infarction.
Mother suffers from arthritis.
Social history:
A married public transport driver. He is a non-smoker and drinks socially. 
Systemic inquiry:
• General Health: looks well in general 
• Cardiovascular System: no abnormalities
• Respiratory System: clear chest
• Gastrointestinal System: constipation, bloated
• Genitourinary System: urinary retention
• Central Nervous System: unstable gait, cannot walk on toes and heels, needs help to stand, impaired 
sensation in a glove and stocking distribution, reduced power of muscles L>R
• Musculoskeletal System: chest pain especially on inspiration
• Endocrine System: no abnormalities
Current Therapy:
 
Immunoglobulins via IV route were given for 5 days in order to suppress the acute inflammatory 
demyelination of the peripheral nervous system.
Discussion of results of general and specific examination:
Neurological examination:
General: The patient did not have any nystagmus or facial asymmetry, but had a slight dysarthria. 
Tone: There was reduced tone in both his upper and lower limbs.
Power: Power assessment showed marked weakness in both upper and lower limbs, being more 
pronounced in the lower limbs, with the left more severe than the right.
Upper limb examination of power:
Muscle Right Limb Left Limb
Deltoid 4 3
Triceps 4 3
3Lower limb examination of power:
Muscle Right limb Left limb
Glutei 3 2
Quadriceps 3 2
Hamstrings 3 2
Iliopsoas 3 2
Reflexes: Reflexes of both upper and lower limbs were reduced. 
Coordination: Upper and lower limb coordination examination was normal. 
Sensation: He had reduced sensation in both his upper and lower limbs.
Gait: He had mild difficulty raising himself from a sitting position.  His gait was unstable and was unable 
to walk on his toes or heels. 
Differential diagnosis:
• GBS
• Mononeuritis multiplex
Diagnostic procedures:
Laboratory exams:
Test: Lumbar Puncture
Justification for test: In order to obtain CSF composition.
Result: Raised protein (889 mg/L) with no cells diagnostic of GBS. 
Conclusion: GBS 
Instrumental exams:
Test: Nerve Conduction Studies and Electromyography
Justification for test: To show any evidence and distribution of a neuropathy 
Result: Findings are consistent with a severe sensori-motor predominantly demyelinating polyneuropathy
            that is compatible with an acute inflammatory neuropathy
Conclusion: GBS
Therapy:
Drugs:
Drug Name (Generic) Dosage Frequency Type Reason
IVIG 0.4g/kg Once daily Immunoglobulin Suppression of              
demyelination
4Diagnosis:
This gentleman’s symptoms were suggestive of GBS. The typical clinical presentation consists of lower 
limb symmetrical parasthaesia that ascends to the upper limbs, progressing to weakness. However, this 
patient’s presentation was atypical since he first complained of a “heavy” feeling of his upper extremities 
which later progressed to parasthaesia. The same later occurred in the lower limbs, thus his presentation 
had a ‘descending’ pattern rather than ‘ascending’. Together with that, he had tongue parasthaesia which 
progressed to dysarthria. In view of these signs and symptoms, a lumbar puncture was done to assess the 
CSF. Elevated protein levels, in the absence of high white blood cell count, was indicative of GBS. EMG 
is a specific and sensitive investigation for GBS since the results were consistent with demyelination.
Final treatment and follow ups:
The patient was started on IVIG which was continued for five days. However he had minimal immediate 
benefit and required intensive rehabilitation. He complained of constipation, urinary retention and 
diplopia. He was transferred to rehab for further physical therapy.
5Fact Box 1
Title: Guillain–Barré syndrome
General overview: GBS is an acute inflammatory immune-mediated disorder affecting the peripheral 
nervous system1. GBS typically manifests as sudden distal symmetrical parasthaesia that ascends to the 
upper limbs and progresses to weakness. A few patients undergo sensory dysfunction especially in the 
demyelinating forms of GBS2. About a third of hospitalised patients are mechanically ventilated due to 
diaphragmatic, respiratory and oropharyngeal muscle weakness3.
Long term signs and symptoms: GBS patients may have persistent weakness, areflexia, ataxia and 
sensory loss. About 7-15% of patients suffer from permanent neurologic sequelae such as bilateral foot-
drop, intrinsic hand muscle wasting, ataxia and dysaesthesia. Moreover, they may experience long-term 
functional impairment and differences in pain intensity4.
Epidemiology: GBS is made up of different subtypes with variable incidence rates in different countries. 
In Europe, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) contributes to 90% of the 
cases. This subtype includes predominantly motor, bilateral facial and pharyngeal disturbances, with 
occasional abnormal sensory and autonomic manifestations5.
Risk  factors: Usually, a bacterial or viral infection such as Campylobacter jejuni, Mycoplasma pneumonia, 
CMV, EBV or influenza virus precede the onset of GBS 6, 7. Surgery has also been shown as a risk 
factor8. Several vaccines have been associated with GBS (mainly past rabies vaccination9, swine flu 
(H1N1) influenza vaccine used in 1976-77 and oral polio vaccination10), but controversy remains for the 
influenza vaccines11. A recent study, however, found an increased risk of GBS with the seasonal influenza 
vaccination12. Moreover, the risk increases with age13.
Prognosis: Up to 85% achieve a full functional recovery within 6-18 months 14. Acute relapse occurs 
in about 10% after initial improvement after treatment 15. Some undergo clinical fluctuations during 
their treatment course. Recurrence of Guillain-Barré syndrome is rare but has been reported in 2-5% 
of patients 16, 17.  Mortality is rare, 2-12% and this occurs due to GBS complications: acute respiratory 
distress syndrome, sepsis, pneumonia, venous thromboembolism, cardiac arrhythmias and arrest. The 
most common cases are due to severe autonomic instability or from the complications of prolonged 
intubation and paralysis 18-21.  
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